| Public | CELG |
| Raised | |
| Post IPO Valuation |
| Website | celgene.com |
| @celgene | |
| Category | BioTech |
| Phone | 908-673-9000 |
| Employees | |
| Founded | 1980 |
| Total | $4.47B |
| Avila Therapeutics, 1/12 | $925M |
| Abraxis BioScience, 6/10 | $2.9B |
| Gloucester Pharmaceuticals, 12/09 | $640M |
| VentiRx Pharmaceuticals | 10/12 |
| Acetylon Pharmaceuticals | 2/12 |
| Acceleron Pharma | 12/11 |
| Agios Pharmaceuticals | 11/11 |
| FerroKin Biosciences | 6/10 |
Celgene Corporation engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases primarily in Europe and the United States. Its primary commercial stage products include REVLIMID for the treatment in combination with dexamethasone for multiple myeloma patients, as well as for the treatment of patients with transfusion-dependent anemia; and THALOMID for the treatment in combination with dexamethasone of patients with newly diagnosed multiple myeloma, as well as for the treatment and suppression of cutaneous manifestations of erythema nodosum leprosum. The company also sells ALKERAN for the palliative treatment of multiple myeloma and of carcinoma of the ovary; VIDAZA, which is used for the treatment of various subtypes of MDS; RITALIN that is used for the treatment of attention deficit hyperactivity disorder; and FOCALIN for the treatment of oncology-related disorders. Its development stage products consist of CC-4047, which is in Phase II trials for the treatment of myelofibrosis and multiple myeloma, and in Phase I trials for the treatment of hemoglobinopathies; CC-10015 that is in pre-clinical stage for the treatment of inflammatory diseases; CC-10004, which is in Phase II clinical trials for the treatment of psoriasis, psoriatic arthritis, and inflammatory diseases; JNK CC-930 that is in Phase I trial to treat fibrotic diseases; Amrubicin, which is in Phase III trials for small cell lung cancer treatment; Human umbilical cord blood, a Phase I trials product to treat transplants and hematological disorders; and ACE-011, a Phase II initiated product for multiple myeloma/Bone loss treatment. Celgene Corporation has strategic collaborations with Acceleron Pharma, Inc. for the joint development and commercialization of ACE-011; and GlobeImmune Inc. to develop molecular immunotherapy for the treatment of cancer. The company was founded in 1980 and is headquartered in Summit, New Jersey.
